Supplementary Figure S3 from The Oncogenic <i>EGFR–SHC1</i> Fusion Confers Insensitivity to EGFR-TKIs via Dual Activation of N-EGFR Kinase Domain and C-SHC1 Phosphorylation Sites in Lung Cancer

<jats:p>&lt;p&gt;Supplementary Figure S3 shows that both the N-terminal EGFR kinase domain and the C-terminal SHC1 phosphorylation sites contribute to the oncogenic properties of EGFR-SHC1, including analyses of SHC1 phosphorylation in response to EGF stimulation, TKI sensitivity in Ba/F3 cells, and functional assessments via soft agar colony formation and IL-3-independent proliferation assays using various EGFR-SHC1 mutants. It also includes immunoblotting validation of protein expression and downstream signaling in cells expressing EGFR-RAD51 and EGFR-SHC1 variants.&lt;/p&gt;</jats:p>